Although ATR inhibition alone was previously shown to prolong survival in in vivo models of B-cell acute lymphoblastic leukaemia, it was insufficient to be therapeutically relevant; however, combined with ATR, RNR and DCK inhibitors, it proved to be an extremely effective strategy against this haematological malignancy (Le et al., 2017). Here, ATR is linked to precursor B-cell acute lymphoblastic leukemia.